PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced that Chief Executive Officer Kenneth Kelley will present at the annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, at 5:00 p.m. Pacific Standard Time.
PaxVax has a strategy of acquiring and developing effective, safe, affordable and easy-to-administer vaccines. In July of 2014, PaxVax acquired the FDA-approved typhoid vaccine Vivotif® from Crucell Switzerland AG and currently manufactures and markets it in the U.S. and Europe. In December of 2014, the company announced that it successfully met primary endpoints in a Phase 3 trial of its single-dose oral cholera vaccine candidate. The company intends to submit a Biologics License Application (BLA) for this product, under the brand name Vaxchora®, to the U.S. FDA in mid-2015. If licensed, Vaxchora would be the first and only single-dose vaccine in the U.S. against cholera making it more convenient for travelers, particularly for those traveling on short notice.
The company has a portfolio of clinical and preclinical vaccine candidates which are supported by numerous grants, contracts, and awards from the NIH through the National Institute of Allergy and Infectious Diseases (NIAID), its Division of Acquired Immunodeficiency Syndrome (DAIDS) and its Division of Microbiology and Infectious Diseases (DMID), as well as the Wellcome Trust and the Bill and Melinda Gates Foundation. PaxVax has raised more than $80 million from investors including Ignition Growth and Venture Partners and Blue Haven Initiative.
About PaxVax
Founded in 2007, PaxVax is a fully integrated specialty vaccine company with a mission to protect people from infectious diseases. The company seeks both financial returns through two specialty business strategies in travel and biodefense vaccines as well as social returns by providing access to its vaccines globally and by developing vaccines addressing some of the world’s most lethal infectious diseases. The PaxVax portfolio includes a licensed vaccine for typhoid (Vivotif®), vaccines in clinical development for cholera, anthrax, HIV, and H5N1 (pandemic bird flu) and in research for malaria, dengue, rabies and Herpes Simplex Virus. PaxVax is headquartered in Redwood City, California and maintains research and development and Good Manufacturing Practice (GMP) facilities in San Diego, California, USA, and its newly acquired facility near Bern, Switzerland. More information is available at www.PaxVax.com.
